ABL1 Tyrosine Kinase Domain Mutation Analysis
Sanger sequencing of ABL1 tyrosine kinase domain to detect imatinib resistance mutations in BCR::ABL1-positive CML, ALL, and AML.
BCR::ABL1 Qualitative Breakpoints p190 vs p210
Qualitative RQ-PCR identification of BCR::ABL1 fusion transcript breakpoint type (major p210 vs minor p190) for diagnosis of CML, ALL, and AML.
BCR::ABL1 IS t(9;22)
Quantitative RQ-PCR detection and monitoring of the t(9;22) BCR::ABL1 fusion transcript (p210 and p190) for CML, ALL, and AML diagnosis and MRD.